Emil Freireich, a pioneer of chemotherapy and ‘towering figure in oncology,’ dies at 93
His success with patients who others believed to be lost causes vastly expanded options for treatment.
By Emily LangerThe Washington Post
Share
Emil Freireich, a physician-scientist who helped engineer effective treatments for childhood leukemia at a time when the disease was considered a death sentence, an advance that magnified the promise of chemotherapy and was credited with saving tens of thousands of lives, died Feb. 1 in Houston. He was 93.
His death was announced by the University of Texas MD Anderson Cancer Center, where Dr. Freireich worked for half a century and where he died. A spokeswoman for the center said that he had covid-19, the disease caused by the novel coronavirus, but that the cause of death has not yet been determined.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ziopharm Oncology Announces Election of Robert Postma to its Board of Directors
ZIOPHARM Oncology IncFebruary 5, 2021 GMT
BOSTON, Feb. 05, 2021 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and long-term shareholder of Ziopharm.
James Huang, Chairman of the Board, said, “We welcome Bob to Ziopharm’s Board of Directors. With his experience and financial acumen, Bob will make an immediate contribution to Ziopharm and I believe the Board is now well positioned to partner with the management team to deliver on our very promising T-cell directed and cytokine technologies and opportunities.”
PDS Biotech Announces Preliminary Efficacy Achievement in Phase II Combination Trial of PDS0101 Led by the National Cancer Institute · The National Cancer Institute s (NCI) Phase II clinical study of PDS Biotech s PDS0101 for HPV-associated cancers has achieved its preliminary objective response. · Full enrollment for the Phase II trial is triggered by observation of 3 objective responses in continued evaluation of the initial group of 8 patients · Milestone for treatment of HPV-associated cancers NetScientific plc (AIM: NSCI), the life sciences, technology, investment and commercialisation company, announces that its portfolio company PDS Biotechnology Corporation ( PDS ) (Nasdaq: PDSB) has achieved its preliminary objective response for the National Cancer Institute s (NCI) Phase II clinical study of PDS0101 for the treatment of advanced human papill